AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 293: E857-E864, 2007. First published July 17, 2007; doi:10.1152/ajpendo.00283.2007
0193-1849/07 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/3/E857    most recent
00283.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matveyenko, A. V.
Right arrow Articles by Donovan, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matveyenko, A. V.
Right arrow Articles by Donovan, C. M.

Portal vein hypoglycemia is essential for full induction of hypoglycemia-associated autonomic failure with slow-onset hypoglycemia

Aleksey V. Matveyenko, MaryAnn Bohland, Maziyar Saberi, and Casey M. Donovan

Departments of Kinesiology and Integrative and Evolutionary Biology, University of Southern California, Los Angeles, California

Submitted 4 May 2007 ; accepted in final form 16 July 2007

Antecedent hypoglycemia leads to impaired counterregulation and hypoglycemic unawareness. To ascertain whether antecedent portal vein hypoglycemia impairs portal vein glucose sensing, thereby inducing counterregulatory failure, we compared the effects of antecedent hypoglycemia, with and without normalization of portal vein glycemia, upon the counterregulatory response to subsequent hypoglycemia. Male Wistar rats were chronically cannulated in the carotid artery (sampling), jugular vein (glucose and insulin infusion), and mesenteric vein (glucose infusion). On day 1, the following three distinct antecedent protocols were employed: 1) HYPO-HYPO: systemic hypoglycemia (2.52 ± 0.11 mM); 2) HYPO-EUG: systemic hypoglycemia (2.70 ± 0.03 mM) with normalization of portal vein glycemia (portal vein glucose = 5.86 ± 0.10 mM); and 3) EUG-EUG: systemic euglycemia (6.33 ± 0.31 mM). On day 2, all groups underwent a hyperinsulinemic-hypoglycemic clamp in which the fall in glycemia was controlled so as to reach the nadir (2.34 ± 0.04 mM) by minute 75. Counterregulatory hormone responses were measured at basal (–30 and 0) and during hypoglycemia (60–105 min). Compared with EUG-EUG, antecedent hypoglycemia (HYPO-HYPO) significantly blunted the peak epinephrine (10.44 ± 1.35 vs. 15.75 ± 1.33 nM: P = 0.01) and glucagon (341 ± 16 vs. 597 ± 82 pg/ml: P = 0.03) responses to next-day hypoglycemia. Normalization of portal glycemia during systemic hypoglycemia on day 1 (HYPO-EUG) prevented blunting of the peak epinephrine (15.59 ± 1.43 vs. 15.75 ± 1.33 nM: P = 0.94) and glucagon (523 ± 169 vs. 597 ± 82 pg/ml: P = 0.66) responses to day 2 hypoglycemia. Consistent with hormonal responses, the glucose infusion rate during day 2 hypoglycemia was substantially elevated in HYPO-HYPO (74 ± 12 vs. 49 ± 4 µmol·kg–1·min–1; P = 0.03) but not HYPO-EUG (39 ± 7 vs. 49 ± 4 µmol·kg–1·min–1: P = 0.36). Antecedent hypoglycemia local to the portal vein is required for the full induction of hypoglycemia-associated counterregulatory failure with slow-onset hypoglycemia.

glucose sensor; sympathoadrenal; counterregulation



Address for reprint requests and other correspondence: C. M. Donovan, Univ. of Southern California, Depts. of Kinesiology and Integrative Biology, 3560 Watt Way, PED 107, Los Angeles, CA 90089-0652 (e-mail: donovan{at}usc.edu)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.